Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Combination of sunitinib and ¹⁷⁷ Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer.

Autor: Oosterwijk-Wakka JC; Radboud university medical center, Department of Urology, 267 Experimental Urology, PO Box 9101, 6500 HB Nijmegen, the Netherlands. Electronic address: jeannette.oosterwijk-wakka@radboudumc.nl., de Weijert MCA; Radboud university medical center, Department of Urology, 267 Experimental Urology, PO Box 9101, 6500 HB Nijmegen, the Netherlands., Franssen GM; Radboud university medical center, Department of Radiology and Nuclear Medicine, PO Box 9101, 6500 HB Nijmegen, the Netherlands., Kolev DR; Radboud university medical center, Department for Health Evidence, PO Box 9101, 6500 HB Nijmegen, the Netherlands., de Haan TAFJ; Radboud university medical center, Department for Health Evidence, PO Box 9101, 6500 HB Nijmegen, the Netherlands., Boerman OC; Radboud university medical center, Animal research facility, PO Box 9101, 6500 HB Nijmegen, the Netherlands., Mulders PFA; Radboud university medical center, Department of Urology, PO Box 9101, 6500 HB Nijmegen, the Netherlands., Oosterwijk E; Radboud university medical center, Department of Urology, 267 Experimental Urology, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Publikováno v: Neoplasia (New York, N.Y.) [Neoplasia] 2022 Oct; Vol. 32, pp. 100826. Date of Electronic Publication: 2022 Jul 22.